Low-Dose BBR3610 Toxicity in Colon Cancer Cells Is p53-Independent and Enhanced by Inhibition of Epidermal Growth Factor Receptor (ERBB1)-Phosphatidyl Inositol 3 Kinase Signaling

We have examined the mechanisms by which the multinuclear platinum chemotherapeutic BBR3610 kills human colon cancer cells. BBR3610 more efficiently killed HCT116, DLD1, SW480, and HT29 cells than BBR3464, cisplatin, or oxaliplatin. The amount of platinum uptake per cell and its incorporation into DNA were identical for BBR3464 and BBR3610. BBR3610 lethality (IC75) was unaltered comparing HCT116 wild-type and p53–/– cells, was reduced in p21–/– cells, and was enhanced in K-RAS D13 null cells. Small molecule or molecular inhibition of epidermal growth factor receptor (ERBB1) or phosphatidyl inositol 3 kinase (PI3K) enhanced BBR3610 toxicity in HCT116, DLD1, and SW480 cells. Small molecule or molecular inhibition of caspase 8 function abolished the toxicity of BBR3610 and of BBR3610 + ERBB1 inhibitor treatments, whereas inhibition of caspase 9 suppressed the ability of ERBB1 inhibitors to enhance BBR3610 lethality. Treatment with BBR3610 reduced AKT activity; the expression of dominant-negative AKT enhanced and expression of constitutively active AKT suppressed, respectively, the toxicity of BBR3610 and of BBR3610 + ERBB1 inhibitor treatments. Treatment with BBR3610 reduced expression of c-FLIP-s and MCL-1, levels that were maintained in cells expressing constitutively active AKT. Overexpression of c-FLIP-s or loss of BID function suppressed BBR3610 toxicity, whereas overexpression of XIAP or Bcl-xL suppressed the potentiation of cell killing by ERBB1 inhibitors. Collectively, our data argue that BBR3610 promotes cell killing via a caspase 8-dependent mechanism, which can be enhanced by ERBB1/PI3K inhibitors that promote additional BBR3610-dependent cell killing via activation of BAX and caspase 9.

[1]  P. Dent,et al.  MEK1/2 inhibitors sensitize Bcr/Abl+ human leukemia cells to the dual Abl/Src inhibitor BMS-354/825. , 2007, Blood.

[2]  P. Fisher,et al.  Radiation-induced cell signaling: inside-out and outside-in , 2007, Molecular Cancer Therapeutics.

[3]  P. Dent,et al.  17-Allylamino-17-demethoxygeldanamycin enhances the lethality of deoxycholic acid in primary rodent hepatocytes and established cell lines , 2007, Molecular Cancer Therapeutics.

[4]  M. Bhat,et al.  p53 regulates ERK activation in carboplatin induced apoptosis in cervical carcinoma: A novel target of p53 in apoptosis , 2007, FEBS letters.

[5]  P. Dent,et al.  Mcl-1 down-regulation potentiates ABT-737 lethality by cooperatively inducing Bak activation and Bax translocation. , 2007, Cancer research.

[6]  John D. Roberts,et al.  Correction to: “Human Chorionic Gonadotropin Modulates Prostate Cancer Cell Survival after Irradiation or HMG CoA Reductase Inhibitor Treatment” , 2016, Molecular Pharmacology.

[7]  R. Schnellmann,et al.  A Death-Promoting Role for Extracellular Signal-Regulated Kinase , 2006, Journal of Pharmacology and Experimental Therapeutics.

[8]  A. Khokhar,et al.  Upregulation of p27 and its inhibition of CDK2/cyclin E activity following DNA damage by a novel platinum agent are dependent on the expression of p21 , 2006, British Journal of Cancer.

[9]  P. Dent,et al.  OSU-03012 Promotes Caspase-Independent but PERK-, Cathepsin B-, BID-, and AIF-Dependent Killing of Transformed Cells , 2006, Molecular Pharmacology.

[10]  T. Mikkelsen,et al.  Polynuclear platinum anticancer drugs are more potent than cisplatin and induce cell cycle arrest in glioma. , 2006, Neuro-oncology.

[11]  M. Socinski,et al.  Phase II study of BBR 3464 as treatment in patients with sensitive or refractory small cell lung cancer , 2006, Anti-cancer drugs.

[12]  A. Hishida,et al.  Inhibition of p21 modifies the response of cortical proximal tubules to cisplatin in rats. , 2006, American journal of physiology. Renal physiology.

[13]  W L Allen,et al.  c-FLIP inhibits chemotherapy-induced colorectal cancer cell death , 2006, Oncogene.

[14]  T. Wilson,et al.  Chemotherapy and TRAIL-mediated colon cancer cell death: the roles of p53, TRAIL receptors, and c-FLIP , 2005, Molecular Cancer Therapeutics.

[15]  U. McDermott,et al.  Effect of p53 status and STAT1 on chemotherapy-induced, Fas-mediated apoptosis in colorectal cancer. , 2005, Cancer research.

[16]  Dong Wang,et al.  Cellular processing of platinum anticancer drugs , 2005, Nature Reviews Drug Discovery.

[17]  Andrew J. Wilson,et al.  Molecular mechanisms of action and prediction of response to oxaliplatin in colorectal cancer cells , 2004, British Journal of Cancer.

[18]  Paul Workman,et al.  Expression of Kinase-defective Mutants of c-Src in Human Metastatic Colon Cancer Cells Decreases Bcl-xL and Increases Oxaliplatin- and Fas-induced Apoptosis* , 2004, Journal of Biological Chemistry.

[19]  M. Morimatsu,et al.  Loss of caspase-8 activation pathway is a possible mechanism for CDDP resistance in human laryngeal squamous cell carcinoma, HEp-2 cells. , 2004, International journal of oncology.

[20]  E. Solary,et al.  Cisplatin-Induced CD95 Redistribution into Membrane Lipid Rafts of HT29 Human Colon Cancer Cells , 2004, Cancer Research.

[21]  D. Bisset,et al.  A phase I study of the trinuclear platinum compound, BBR 3464, in combination with protracted venous infusional 5-fluorouracil in patients with advanced cancer , 2004, Cancer Chemotherapy and Pharmacology.

[22]  Z. Siddik,et al.  Cisplatin: mode of cytotoxic action and molecular basis of resistance , 2003, Oncogene.

[23]  Paul Dent,et al.  MAPK pathways in radiation responses , 2003, Oncogene.

[24]  P. Dent,et al.  Conversion of Drug-Induced Differentiation to Apoptosis by Pharmacologic Cyclin-Dependent Kinase Inhibitors , 2002, Cell cycle.

[25]  Fengqin Gao,et al.  A Functional Role for the B56 α-Subunit of Protein Phosphatase 2A in Ceramide-mediated Regulation of Bcl2 Phosphorylation Status and Function* , 2002, The Journal of Biological Chemistry.

[26]  T. Ried,et al.  Centrosome abnormalities, recurring deletions of chromosome 4, and genomic amplification of HER2/neu define mouse mammary gland adenocarcinomas induced by mutant HER2/neu , 2002, Oncogene.

[27]  N. Farrell,et al.  BBR 3464: a novel triplatinum complex, exhibiting a preclinical profile of antitumor efficacy different from cisplatin. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[28]  N. Farrell.  Polynuclear Charged Platinum Compounds as a New Class of Anticancer Agents: Toward a New Paradigm , 2000 .

[29]  N. Farrell,et al.  Platinum-Based Drugs in Cancer Therapy , 2000, Cancer Drug Discovery and Development.

[30]  C. Giandomenico,et al.  Current status of platinum-based antitumor drugs. , 1999, Chemical reviews.

[31]  B. Tsang,et al.  Sustained suppression of Fas ligand expression in cisplatin-resistant human ovarian surface epithelial cancer cells , 1999, Apoptosis.

[32]  N. Farrell,et al.  A novel charged trinuclear platinum complex effective against cisplatin-resistant tumours: hypersensitivity of p53-mutant human tumour xenografts , 1999, British Journal of Cancer.

[33]  I. Viano,et al.  A novel trinuclear platinum complex overcomes cisplatin resistance in an osteosarcoma cell system. , 1999, Molecular pharmacology.

[34]  G. Schwartz,et al.  Evidence for involvement of mitogen-activated protein kinase, rather than stress-activated protein kinase, in potentiation of 1-beta-D-arabinofuranosylcytosine-induced apoptosis by interruption of protein kinase C signaling. , 1998, Molecular pharmacology.

[35]  P. Fisher,et al.  Inhibition of the mitogen activated protein (MAP) kinase cascade potentiates cell killing by low dose ionizing radiation in A431 human squamous carcinoma cells , 1998, Oncogene.

[36]  N. Normanno,et al.  Anti‐sense oligonucleotides directed against EGF‐related growth factors enhance anti‐proliferative effect of conventional anti‐tumor drugs in human colon‐cancer cells , 1997, International journal of cancer.

[37]  L. Kèlland,et al.  New platinum antitumor complexes. , 1993, Critical reviews in oncology/hematology.

[38]  Shirley A. Miller,et al.  A simple salting out procedure for extracting DNA from human nucleated cells. , 1988, Nucleic acids research.

[39]  K. Harrap.  Preclinical studies identifying carboplatin as a viable cisplatin alternative. , 1985, Cancer treatment reviews.

[40]  N. Farrell.  Polynuclear platinum drugs. , 2004, Metal ions in biological systems.

[41]  M. Fojta,et al.  Differential recognition by the tumor suppressor protein p53 of DNA modified by the novel antitumor trinuclear platinum drug BBR3464 and cisplatin. , 2004, Nucleic acids research.

[42]  E. Solary,et al.  Cisplatin-Induced CD 95 Redistribution into Membrane Lipid Rafts of HT 29 Human Colon Cancer Cells , 2004 .

[43]  G. Giaccone,et al.  The epidermal growth factor receptor pathway and its inhibition as anticancer therapy. , 2003, Drugs of today.

[44]  L. Desantis,et al.  Travoprost: a potent ocular hypotensive agent. , 2003, Drugs of today.